-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$14.67244.37% Upside
Inozyme Pharma, Inc. Frequently Asked Questions
-
What analysts cover Inozyme Pharma, Inc.?
Inozyme Pharma, Inc. has been rated by research analysts at Stifel Nicolaus, Wells Fargo, H.C. Wainwright in the past 90 days.